238 related articles for article (PubMed ID: 15200750)
1. Establishing the dosage equivalency of oxymorphone extended release and oxycodone controlled release in patients with cancer pain: a randomized controlled study.
Gabrail NY; Dvergsten C; Ahdieh H
Curr Med Res Opin; 2004 Jun; 20(6):911-8. PubMed ID: 15200750
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of oxymorphone extended release in chronic low back pain: results of a randomized, double-blind, placebo- and active-controlled phase III study.
Hale ME; Dvergsten C; Gimbel J
J Pain; 2005 Jan; 6(1):21-8. PubMed ID: 15629415
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness and safety of oral extended-release oxymorphone for the treatment of cancer pain: a pilot study.
Sloan P; Slatkin N; Ahdieh H
Support Care Cancer; 2005 Jan; 13(1):57-65. PubMed ID: 15538638
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and tolerability of once-daily OROS hydromorphone and twice-daily extended-release oxycodone in patients with chronic, moderate to severe osteoarthritis pain: results of a 6-week, randomized, open-label, noninferiority analysis.
Hale M; Tudor IC; Khanna S; Thipphawong J
Clin Ther; 2007 May; 29(5):874-888. PubMed ID: 17697906
[TBL] [Abstract][Full Text] [Related]
5. A comparison of daily average consumption (DACON) of oxycodone and oxymorphone long-acting oral tablets.
Rubino M; Summers KH; Puenpatom A; Fu C; Ohsfeldt RL; Ben-Joseph RH
J Manag Care Pharm; 2011 Jun; 17(5):367-76. PubMed ID: 21657806
[TBL] [Abstract][Full Text] [Related]
6. Oxymorphone extended release for the treatment of chronic low back pain: a retrospective pooled analysis of enriched-enrollment clinical trial data stratified according to age, sex, and prior opioid use.
Peniston JH; Gould E
Clin Ther; 2009 Feb; 31(2):347-59. PubMed ID: 19302907
[TBL] [Abstract][Full Text] [Related]
7. Factors affecting acceptability of titrated oxymorphone extended release in chronic low back pain - an individual patient analysis.
Peniston JH; Xiang Q; Gould EM
Curr Med Res Opin; 2010 Aug; 26(8):1861-71. PubMed ID: 20521870
[TBL] [Abstract][Full Text] [Related]
8. A 2-week, multicenter, randomized, double-blind, placebo-controlled, dose-ranging, phase III trial comparing the efficacy of oxymorphone extended release and placebo in adults with pain associated with osteoarthritis of the hip or knee.
Kivitz A; Ma C; Ahdieh H; Galer BS
Clin Ther; 2006 Mar; 28(3):352-64. PubMed ID: 16750450
[TBL] [Abstract][Full Text] [Related]
9. Double-blind, randomized comparison of the analgesic and pharmacokinetic profiles of controlled- and immediate-release oral oxycodone in cancer pain patients.
Stambaugh JE; Reder RF; Stambaugh MD; Stambaugh H; Davis M
J Clin Pharmacol; 2001 May; 41(5):500-6. PubMed ID: 11361046
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and tolerability of oxymorphone immediate release for acute postoperative pain after abdominal surgery: a randomized, double-blind, active- and placebo-controlled, parallel-group trial.
Aqua K; Gimbel JS; Singla N; Ma T; Ahdieh H; Kerwin R
Clin Ther; 2007 Jun; 29(6):1000-12. PubMed ID: 17692717
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of once-daily hydromorphone extended-release versus twice-daily oxycodone hydrochloride controlled-release in chinese patients with cancer pain: a phase 3, randomized, double-blind, multicenter study.
Yu S; Shen W; Yu L; Hou Y; Han J; Richards HM
J Pain; 2014 Aug; 15(8):835-44. PubMed ID: 24846822
[TBL] [Abstract][Full Text] [Related]
12. Titration with oxymorphone extended release to achieve effective long-term pain relief and improve tolerability in opioid-naive patients with moderate to severe pain.
Rauck R; Ma T; Kerwin R; Ahdieh H
Pain Med; 2008 Oct; 9(7):777-85. PubMed ID: 18950436
[TBL] [Abstract][Full Text] [Related]
13. Controlled-release oxycodone and morphine in cancer related pain.
Heiskanen T; Kalso E
Pain; 1997 Oct; 73(1):37-45. PubMed ID: 9414055
[TBL] [Abstract][Full Text] [Related]
14. A 12-week, randomized, placebo-controlled trial assessing the safety and efficacy of oxymorphone extended release for opioid-naive patients with chronic low back pain.
Katz N; Rauck R; Ahdieh H; Ma T; Gerritsen van der Hoop R; Kerwin R; Podolsky G
Curr Med Res Opin; 2007 Jan; 23(1):117-28. PubMed ID: 17257473
[TBL] [Abstract][Full Text] [Related]
15. Positive and negative subjective effects of extended-release oxymorphone versus controlled-release oxycodone in recreational opioid users.
Schoedel KA; McMorn S; Chakraborty B; Potts SL; Zerbe K; Sellers EM
J Opioid Manag; 2011; 7(3):179-92. PubMed ID: 21823549
[TBL] [Abstract][Full Text] [Related]
16. Oxymorphone extended-release tablets relieve moderate to severe pain and improve physical function in osteoarthritis: results of a randomized, double-blind, placebo- and active-controlled phase III trial.
Matsumoto AK; Babul N; Ahdieh H
Pain Med; 2005; 6(5):357-66. PubMed ID: 16266356
[TBL] [Abstract][Full Text] [Related]
17. The efficacy and safety of oral immediate-release oxymorphone for postsurgical pain.
Gimbel J; Ahdieh H
Anesth Analg; 2004 Nov; 99(5):1472-1477. PubMed ID: 15502051
[TBL] [Abstract][Full Text] [Related]
18. Randomized, double-blind, cross-over trial comparing safety and efficacy of oral controlled-release oxycodone with controlled-release morphine in patients with cancer pain.
Bruera E; Belzile M; Pituskin E; Fainsinger R; Darke A; Harsanyi Z; Babul N; Ford I
J Clin Oncol; 1998 Oct; 16(10):3222-9. PubMed ID: 9779695
[TBL] [Abstract][Full Text] [Related]
19. Fentanyl buccal tablet compared with immediate-release oxycodone for the management of breakthrough pain in opioid-tolerant patients with chronic cancer and noncancer pain: a randomized, double-blind, crossover study followed by a 12-week open-label phase to evaluate patient outcomes.
Webster LR; Slevin KA; Narayana A; Earl CQ; Yang R
Pain Med; 2013 Sep; 14(9):1332-45. PubMed ID: 23855816
[TBL] [Abstract][Full Text] [Related]
20. Long-term tolerability and effectiveness of oxymorphone extended release in patients with cancer.
Slatkin NE; Rhiner MI; Gould EM; Ma T; Ahdieh H
J Opioid Manag; 2010; 6(3):181-91. PubMed ID: 20642247
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
